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Background: Intraoperative radiotherapy (IORT) refers to the delivery of a high dose of radia-
tion at the time of surgery.
Aim: To analyze clinical and research-oriented innovative activities developed in a 17-year
period using intraoperative electron-radiation therapy (IOeRT) as a component of treatment
in  a multidisciplinary approach for cancer management.
Materials and methods: From 01/1995 to 03/2012 IOeRT procedures were registered in a spe-
ciﬁc  Hospital-based database. Research and developments in imaging and recording for
treatment planning implementation are active since 2006.
Results: 1004 patients were treated and 1036 IORT procedures completed. Median age of
patients was 61 (range 5 months to 94 years). Gender distribution was male in 54% of
cases  and female in 46%. Disease status at the time of IORT was 796 (77%) primary andCancer type distribution included: 62% gastrointestinal, 18% sarcoma,240  (23%) recurrent. 5%  pancreas, 2% paediatric, 3% breast, 77 7% oligotopic recurrences, 2% other. IORT techni-
cal characteristics were: Applicator size 5 cm 22%, 6 cm 21%, 7 cm 21%, 8 cm 15%, 9 cm 6%,
10  cm 7% 12 cm 5% 15 cm 3%. Electron energies: 6 MeV 19%, 8 MeV 15%, 10 MeV 15%, 12 MeV
23%, 15 MeV 19%, 18 MeV 6%, other 3%. Multiple ﬁelds: 108 (11%). Dose: 7.5 Gy 3%, 10 Gy 35%,
12  Gy 3%, 12.5 Gy 49%, 15 Gy 5%, other 5%.
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Conclusion: An IORT programme developed in an Academic Hospital based on practice-
oriented medical decisions is an attractive interdisciplinary oncology initiative proven to
be  able to generate an intensive clinical activity for cancer patient quality care and a com-
petitive source of scientiﬁc patient-oriented research, development and innovation.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
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12.5 Gy 49%, 15 Gy 5%, other 5%..  Background
ntraoperative radiotherapy (IORT) refers to the delivery of a
igh dose of radiation at the time of surgical intervention.
ORT achieves highly effective radiation doses to a speciﬁc
arget while dose-limiting healthy structures are surgically
isplaced or shielded. This procedure uses a multidisciplinary
pproach in the treatment of cancer emphasizing an interac-
ion between surgery and radiotherapy by minimizing surgical
esidue, maximizing the radiobiological effects of a single
igh dose of radiation and optimizing the duration of the
reatment.1
The modern approach to IORT began in the early 60 s with
tudies by Abe at the University of Kyoto using single high
ose of gamma-rays of cobalt unit and electrons of betatron. In
970, special IOERT facilities with in-room conventional linear
ccelerators were equipped at the Howard University Hospital
nd the Massachusetts General Hospital. In the early 90s, ded-
cated mobile electron linear accelerators and a miniaturized
ow-energy X-rays machine were introduced to the clinical
ractice in a number of radiotherapy centres worldwide.2
.  Aim
his article aims to report the data collected by a database reg-
stry from 17 years of experience in performing this procedure
n an Academic European Hospital (Hospital General Univer-
itario Gregorio Maran˜ón, Madrid, Spain) with particular focus
n clinical and technical aspects of IORT treatments. The type
f IORT programme developed in this institution involves the
pplication of electron beams. Two non-dedicated ﬁxed lin-
ar accelerators are available, requiring transportation from
he operating room to the accelerator in all procedures. In this
ime-frame several research projects have been implemented
o extend technological knowledge for treatment planning.3
.  Materials  and  methods
rom 01/1995 to 03/2012 IORT procedures were recorded in
 speciﬁc database registry where real-time or retrospective
ata was entered. Information was integrated in order to
nalyze clinical and technical parameters of the treatment
rogrammes including the IORT component. The data-base
egistered the following demographic, clinical and technical
nformation: (a) anonymized patient data including age,
ender, performance status according to Karnofsky scale; (b)
umour data including site, histology, grading, staging accord-
ng to TNM classiﬁcation, primary or recurrent tumour status
t IORT evaluation; (c) treatment data including treatmentrights reserved.
intent, extension of surgery, data of surgery and treatment
strategy; (d) speciﬁc IORT data included IORT  use prior/after
tumour removal, number of ﬁelds, applicator diameter and
bevel angle, energy and type of radiation, radiotherapy
device, total dose, use of bolus, reference isodose. Data
collection for the purpose of the present analysis ended in
March 2012.
4.  Results
Since 1995, data from 1036 procedures were collected and
1004 patients were treated. Median age of patients was
61 ranging 5 months to 94 years. Gender distribution was
male in 54% of cases and female in 46%. Cancer site and
disease status at the time of IORT was 796 (77%) primary
and 240 (23%) recurrent. The intent of the treatment was
curative in 98% of the cases and palliative in 2%. Cancer
type distribution was: Gastro-intestinal 641 (62%) (includ-
ing 553 (53%) colorectal and 88 (9%) esophago-gastric), 190
(18%) sarcoma, 55 (5%) pancreas, 19 (2%) paediatric, 31
(3%) breast, 77 (7%) oligotopic recurrences, 23 (2%) other.
The following tumour sites/histologies are included in the
last two categories in order of frequency: gynaecologic
(cervix, endometrium, ovary, vagina, vulva), urologic (kidney,
bladder, testicle), keloid, chordoma, hepatobiliary, adrenal,
lymphoma, schwanoma, sacroiliac thyroid metastases,
spleen.
The type of surgery performed involved radical residue
in 89% of the cases, microscopic residue in 3%, macro-
scopic residue in 7% and no resection in 1% of the cases.
Rectal cancer and sarcomas, because of the large number
of patients treated, are the tumours that most frequently
received each type of surgery whereas pancreatic and
cervix cancers were the most commonly treated after a
non resective intervention. The collaborating surgical spe-
cialties and their rate of involvement are the following:
General Surgeons 76%, Orthopaedic Surgeons 12%, Gynae-
cologists 8%, Paediatric Surgeons 2%, Urologists 1% and
Dermatologists 1%.
IORT technical characteristics included the following
items: (a) Applicator size: 5 cm 22%, 6 cm 21%, 7 cm 21%, 8 cm
15%, 9 cm 6%, 10 cm 7% 12 cm 5% 15 cm 3%.
(b) Electron energies: 6 MeV 19%, 8 MeV 15%, 10 MeV 15%,
12 MeV 23%, 15 MeV 19%, 18 MeV 6%, other 3%. (c) Multiple
ﬁelds: 108 (11%). (d) Dose: 7.5 Gy 3%, 10 Gy 35%, 12 Gy 3%,Cancellation rate is estimated at 15%. Anaesthesia time
ranged from 1 h to 14 h, median 4 h. Median IORT  time (includ-
ing transportation) was 50 min  (range 20–120 min).
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Fig. 1 – Institutional 5-years period analysis of the IORT
programme: cancer sites.
Fig. 2 – Cancer site vs. applicator diameter selected in
technical common indications of IOERT.
Fig. 3 – Cancer site vs. electron beam energy indicated in
from 1995 to 2009, the distribution of the tumours most
frequently treated with IORT remained practically constant,
while in the last 2 years the treatment of breast cancer was4.1.  Institutional  activity:  indications  vs.  time
Fig. 1 describes the total performance and types of cancer in
the IORT programme along the 17 years of activity in 5-year
periods. This activity has proven to be stable.
From 1995 to 1999: 255 IORT treatments were performed.
Median age was 61 years with a range from 5 months to 94
years. Gender distribution during this period was male in 57%
of the cases and female in 43%. The most prevalent tumours
were rectum in 52%, sarcoma in 17%, and esophago-gastric in
8%.
From 2000 to 2004: 301 patients were treated. Median age
of the patients was 58 years (range 1–80 years). Gender distri-
bution was male in 60% and female in 30% of the cases. The
most treated tumours types were rectum in 52%, sarcoma in
17% and esophago-gastric in 12%.
From 2005 to 2009: 333 IORT procedures were performed.
Median age was 63 years with a range from 8 months to 88
years. Gender distribution was male in 52% and female in 48%.
The most frequently treated tumours were rectum in 58%,
sarcomas in 18% and esophago-gastric in 4%.
From 2010 to 2012: 147 patients received IORT treatments.
Median age was 62 years (range 2–85 years). Gender distribu-
tion was female in 58% and male in 42%. The most prevalent
tumours were rectum in 40%, sarcoma 22% and breast in 12%.
4.2.  Technical  characteristics  of  IORT:  correlations  with
cancer sites  and  status
A description of applicator (Fig. 2), energy (Fig. 3) and dose
(Fig. 4) performance in common IOERT indications. A speciﬁc
analysis of IOERT technical characteristics is described for the
dominant diseases treated (Tables 1 and 2).
5.  Discussion
The interest of the survey involved the understanding that
prospective registry of data is an optimized clinical practice
and can lead to promote quality in the development of this
treatment modality.
Following a general review of the data obtained, it is
stressed that the intent of the delivered treatments is almost
exclusively curative and that in a high percentage the disease
status at the time of IORT is primary at the time of initialIOERT procedures.
diagnosis. The type of surgery performed involves radical
resection in a vast majority of cases.
After analysing the data distributed in 5-year periods,
the results show that during the ﬁrst three periods coveredFig. 4 – Dose delivered according to tumour site.
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Table 1 – IORT technical parameters for all tumour sites.
Rectal cancer
(primary) (%)
Rectal cancer
(recurrent) (%)
Soft tissues
sarcomas
(%)
Esophago-
gastric
(%)
Pancreatic
cancer (%)
Paediatric
cancer (%)
Breast
cancer (%)
Applicator diameters
5 cm 26 30 7 5 – 63 90
6 cm 37 20 6 11 6 11 10
7 cm 30 16 10 28 21 21 –
8 cm 6  16 11 43 51 5 –
9 cm – 3 11 9 16 – –
10 cm – 9 22 4 6 – –
12 cm – 3 22 – – – –
15 cm – 3 11 – – – –
Other 1 – – – – – –
Electron beam energy
4 MeV – – 3 – – 16 –
6 MeV 1 16 37 37 18 42 74
8 MeV 5 11 24 30 33 11 4
10 MeV 19 16 11 12 15 5 6
12 MeV 35 24 13 16 8 16 16
15 MeV 33 20 7 – 8 10 –
18 MeV 7 13 5 – 18 – –
Other – – – 5 – – –
Dose delivered
5 Gy –  – 2 – – 11 –
7.5 Gy – – 6 4 – 32 –
10 Gy 24 27 43 64 22 57 42
12 Gy – – 6 6 – – –
12.5 Gy 73 64 39 26 42 – –
15 Gy 3 5 4 – 30 – –
18 Gy – – – – 2 – –
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r21 Gy – – – 
Other – 4 – 
ntroduced replacing esophago-gastric tumours as the third
ost frequently treated type with this technique. This fact
lso entailed a change in gender distribution.
Rectal cancer is, according to the data, the most frequent
umour site treated with IORT. This fact remains constant
long all the extension of the survey. The IORT in rectal can-
er aims to improve local control in locally advanced high-risk
isease and in recurrent tumours where pelvic recurrence
s responsible for therapeutic failure. Numerous literature
tudies showed a favourable local effect of IORT with high
ates of local control in advanced primary cases and in recur-
ent tumours4–8 but the only randomized trial conducted in
Table 2 – Clinical and therapeutic correlations of surgical perfor
cancer site.
Rectum
(primary)
(%)
Rectum
(recurrent)
(%)
Soft tissues
(%)
Primary 100 0 61 
Recurrent 0 100 39 
Curative 100 89 98 
Palliative 0 11 2 
Radical resection 98 84 84 
Surgical residue 2 16 16 
No resection 0 0 0 
Single ﬁeld 98 89 80 
Multiple ﬁeld 2 11 20 – – – 58
– 4 – –
142 patients comparing conventional preoperative external
radiotherapy (40 Gy) and with the same treatment plus IORT
(15–18 Gy) failed to show an advantage for the experimental
arm.9 A recent meta-analysis extensively reviews IOERT stud-
ies in rectal cancer with a positive interpretation of results.10
A distinction was made between primary rectal cancers and
local recurrences. Data show that whereas primary disease
had an exclusively curative treatment intention and a rad-
ical resection was achieved in almost every case, in local
recurrences surgical residue was left in 16% of the cases and
palliative treatment intention was performed in 11%. Treat-
ment technical parameters are quite similar in terms of dose
mance and technical IOERT characteristics according to
Esophago-
gastric
(%)
Pancreas
(%)
Paediatric
(%)
Breast (%)
96 96 65 100
4 4 35 0
100 87 90 100
0 13 10 0
98 56 90 100
2 32 10 0
0 12 0 0
77 100 89 100
23 0 11 0
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and energy, whereas smaller applicators were required in pri-
mary disease. Also the need for multiple ﬁelds was higher in
the treatment of local recurrences.
IORT is an anticipated radiation boost option in the multi-
modality treatment of soft-tissue sarcoma, especially because
it enables the application of dose-dense irradiation to the tar-
get volume, or makes possible a lower EBRT target dose with
corresponding inferior dose to surrounding healthy tissues.
Sarcomas are the second most treated tumours, maintaining
a constant percentage of cases during the 5-year periods eval-
uated. The intent of the treatments was almost exclusively
curative with a high rate of radical resection. In terms of tech-
nical aspects, soft tissue sarcoma required a wide range of
applicator diameters, most likely in relation with the hetero-
geneous tumour extension and post-resection tumour bed.
Moreover, some cases required complex irradiations with mul-
tiple ﬁelds, with high energy electrons up to 18 MeV  and doses
up to 15 Gy.
IORT has potential utility in the treatment of oesophageal
and gastric malignancies, in which the radiation tolerance
of normal organs limits the dose that can be given with
conventional radiotherapy techniques. Treatment of gastric
cancer has a local failure in 50–70% of patients, mainly in
those where an optimal surgery is not achieved. Therefore,
radiation therapy has been shown to decrease local recur-
rence. After a number of studies,11–13 it is possible to conclude
that IORT is a treatment option with contradictory evidence,
although it looks like its inclusion in the treatment of stom-
ach cancer can decrease loco-regional recurrence, it does not
appear to have an impact on overall survival. Similarly, it
does not seem to cause an increase in morbidity or mortal-
ity. Our group has recently reported favourable results both in
gastric and in gastro-oesophageal cancer treated with IORT-
containing multimodal therapy.14,15 According to the data, all
treatments were performed with a curative intention and the
surgery involved radical resection almost exclusively. The dose
delivered was up to 12.5 Gy with relatively low predominat-
ing energies. The diameter of the applicators ranged from 5
to 10 cm and the highest rates in the application of multiple
ﬁelds were obtained.
Pancreatic cancer is still one of the most lethal malig-
nancies with an overall survival of less than 5% at 5 years.
Only 20–40% of cases are operable, and even when a radical
resection with negative margins is obtained, 5-year survival
does not exceed 30%, with half of the surviving patients going
to have a local recurrence over the next 5 years despite the
use of preoperative or postoperative EBRT. Therefore, IORT
could be an interesting therapeutic approach for this dis-
ease for dose intensiﬁcation to improve local control in locally
advanced cases. The potential of IORT in selected pancreatic
cancer was widely reported by international experts.16,17 Pan-
creatic cancer, according to the results, is almost the only
cancer type, followed by a single case of cervix cancer that
received IORT after a non-resective surgery and the third in
frequency to be left with macroscopic or microscopic residue
after surgical intervention. Despite this data, the treatments
were performed with curative intent in the majority of cases.
From the technical point of view, quite large diameters of
applicators, i.e. up to 10 cm,  were used with a large range of
beam energy and dose levels most likely depending on theiotherapy 1 9 ( 2 0 1 4 ) 246–252
presence or removal of the pancreas and possible lymph node
involvement, respectively.
Outcomes in paediatric tumours have improved consider-
ably in the last decades. 80% of all children currently diagnosed
are expected to be long-term survivors in almost every dis-
ease site and histology due to advancements in combined
modality therapies. Because of dose-limiting organs in the
abdomen and pelvis, adequate local control with acceptable
treatment morbidity remains a problem in the treatment on
these locations. This is the reason why IORT is an attractive
treatment option for these locations. Other possible situa-
tions for the use of IORT in paediatric malignancies include
those in which surgery and/or chemotherapy would not be
expected to result in local control or in which EBRT doses
in excess of 50 Gy would be necessary. In addition, there
are cases in which the substitution of IORT for a part of
the EBRT dose would decrease the dose to normal struc-
tures, and, therefore, minimize damage in these tissues.
Data conclude that radical resection was achieved in all
curative treatments. Technical parameters reveal the use of
doses up to 10 Gy with a high range of energies, predomi-
nantly low energies as 6 MeV. The applicator size was variable
but 5 cm applicators were used in more  than half of the
cases.18
In the last decades, clinical indications to IORT treatment
have evolved signiﬁcantly and expert centres incorporated
this technique to the treatment of breast cancer. As the results
show, the incorporation of breast cancer in this treatment
modality is relatively late, but in the last 2 years the num-
ber of treatments performed became the third in terms of
frequency. This fact might be related to a number of fac-
tors including the increasingly higher incidence of breast
cancer and the launch of large clinical trials exploring IORT
as a single radiation modality in an effort to shorten the
overall treatment time of loco-regional therapy of breast
cancer, and its implications.19,20 The evidence of the efﬁ-
cacy of a single fraction of IORT, that represents a partial
breast irradiation (PBI) strategy, is emerging in the last few
years in particular for selected groups of patients.21–23 In this
regard, ESTRO and ASTRO recently formulated quite simi-
lar general criteria for the recommendation of PBI based on
age, tumour stage, histology and hormonal receptor status.
More than half of the patients of this survey were treated
with this single radiation modality using a dose of 21 Gy.
In patients who do not fulﬁl these criteria, the approach as
anticipated boost is adopted as a current practice to boost
the tumour bed, which was the strategy used in the other
42% of the patients. In expert IORT institutions, dose inten-
siﬁcation has proven to result in outstanding low rates of
local recurrence in already reported clinical studies.24 The
range of electron beams energy and collimator size (6 MeV
and 5–6 cm being most frequently used) was most likely
related to the tumour stage and to the size and shape of
the breast but also to the extension of surgical incision for
tumorectomy.
Recurrent pelvic disease and oligotopic intra-abdominal
cancer are indications for surgical rescues that can be com-
pleted by IORT and external radiotherapy. Results along the
last 20 years of publications are consistent with a potential
for cure and acceptable tolerability.25,8
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.  Conclusions
he data presented gives an overview on practice oriented
atients selection, describes treatment modalities, analyses
ethodology and treatment related decisions for a num-
er of tumour types which are treated and may beneﬁt
rom this technique.26,27 The opportunity to transfer radio-
urgical expertise into technological developments (treatment
lanning system) is a remarkable feature that should be
mphasized. Further data analysis will serve as a basis for
esigning clinical trials in an effort to deﬁne the contribution
f IORT in tailored multimodality approach. Opportunities for
rospective technological and biological research in IORT pro-
rammes have been recently reported.14 Technological funded
esearch in our group has covered much of treatment plan-
ing and dosimetry, image  guided simulation, automation and
re-robotic IOERT, clinical practice normalization and self-
raining.
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